• Priovant, backed by Roivant, began enrolling subjects in a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, with first patients enrolled in March 2026.
• Prior results have already been reported from an investigator-initiated, placebo-controlled study that supported moving brepocitinib into rapid development for this indication.
• Program targets a scalp disorder that can cause generally irreversible scarring hair loss with significant pain and itching, with no FDA-approved treatments.
• Expansion adds a fourth late-stage indication for brepocitinib, extending strategy to build a multi-indication rare rheumatology-dermatology franchise ahead of an expected dermatomyositis launch in September.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604020500PRIMZONEFULLFEED9683208) on April 02, 2026, and is solely responsible for the information contained therein.